初次全膝关节置换术中创口内万古霉素粉的全身暴露与肾脏安全性
这项前瞻性对照队列研究纳入260例初次全膝关节置换患者,万古霉素组130例在关闭切口前创口内使用1克万古霉素粉,对照组130例。结果显示术后12小时血清万古霉素浓度普遍极低,急性肾损伤发生率两组相近(6.9%对6.2%),感染与伤口并发症无显著差异,不支持常规预防性使用。
要点
- 创口内1克万古霉素粉全身吸收极少,12小时血清浓度多低于检测下限。
- 万古霉素组与对照组急性肾损伤发生率相近,未见临床有意义的肾毒性信号。
- 感染及伤口并发症无统计学显著下降,不支持初次全膝关节置换常规预防使用。
核心结论
- 初次全膝关节置换创口内使用1克万古霉素粉全身暴露极小,无临床有意义的肾毒性信号,但未显著降低感染或伤口并发症,故不支持常规预防性使用。
研究设计与样本
- 前瞻性对照队列研究,单中心三级医疗中心纳入260例初次全膝关节置换患者,万古霉素组与对照组各130例。
- 万古霉素组在关闭切口前创口内给予1克万古霉素粉,术后12小时检测血清万古霉素浓度。
- 全部患者分析系列肾功能及依据KDIGO定义的急性肾损伤,完成至少6个月随访者评估感染与伤口并发症。
主要发现
- 130例中104例(80.0%)术后12小时血清万古霉素浓度低于实验室报告下限(小于1.00 mg/L)。
- 其余26例有数值者中位浓度为0.28 mg/L(四分位距0.21至1.26;范围0.01至2.76 mg/L),远低于全身治疗水平。
- 血清万古霉素浓度与早期血清肌酐或估算肾小球滤过率变化无相关性(Spearman ρ范围-0.08至-0.03;所有P≥0.720)。
- 急性肾损伤在万古霉素组9例(6.9%)、对照组8例(6.2%)(比值比1.13;95%置信区间0.42至3.04;P=1.000),万古霉素组均为1期。
- 两组手术相关并发症率相近,假体周围关节感染、浅表感染或伤口裂开无统计学显著差异。
关键数值与推荐
- 创口内万古霉素剂量为1克,于关闭切口前给予。
- 术后12小时血清万古霉素浓度低于1.00 mg/L者占80.0%(104/130)。
- 急性肾损伤比值比1.13(95%置信区间0.42至3.04;P=1.000)。
- 血清万古霉素浓度与肾功能早期变化的Spearman ρ为-0.08至-0.03(所有P≥0.720)。
临床怎么用
- 可据此向患者说明创口内1克万古霉素粉全身吸收极少、未见临床有意义的肾毒性信号。
- 因感染与伤口并发症未显著减少,不宜将创口内万古霉素粉作为初次全膝关节置换的常规预防措施。
局限性
- 单中心前瞻性对照队列设计,非随机对照试验。
- 感染与伤口并发症仅在完成至少6个月随访的患者中评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Periprosthetic joint infection is a devastating complication after total knee arthroplasty (TKA). Intrawound vancomycin powder has been proposed as a local prophylactic measure, but concerns remain regarding systemic absorption and nephrotoxicity. This study evaluated systemic absorption, renal safety, and postoperative infection outcomes after intrawound vancomycin use in primary TKA. METHODS: This prospective comparative cohort study included 260 patients who underwent primary TKA at a single tertiary care center: 130 in the vancomycin cohort and 130 in the control cohort. The vancomycin cohort received one gram of intrawound vancomycin powder before closure. Serum vancomycin levels were measured 12 hours postoperatively. Serial renal function and Kidney Disease: Improving Global Outcomes-defined acute kidney injury (AKI) was analyzed in all patients. Infection and wound complication outcomes were assessed in patients who completed at least six months of follow up. RESULTS: The 12-hour serum vancomycin levels were below the laboratory reporting threshold (less than 1.00 mg/L) in 104 of 130 patients (80.0%). Among the remaining 26 patients who had numerical values, the median concentration was 0.28 mg/L (interquartile range, 0.21 to 1.26; range, 0.01 to 2.76 mg/L), which was well below systemic therapeutic levels. The serum vancomycin concentration was not correlated with early changes in serum creatinine or estimated glomerular filtration rate (Spearman ρ range, -0.08 to -0.03; all P ≥ 0.720). AKI occurred in nine patients (6.9%) in the vancomycin group and eight patients (6.2%) in the control group (odds ratio, 1.13; 95% confidence interval, 0.42 to 3.04; P = 1.000). All AKI events in the vancomycin group were stage 1. The surgery-related complication rates were similar between groups, with no statistically significant differences in periprosthetic joint infection, superficial infection, or wound dehiscence. CONCLUSION: Intrawound administration of one gram of vancomycin powder in primary TKA resulted in minimal systemic exposure and showed no clinically meaningful nephrotoxicity signal. However, it was not associated with a statistically significant reduction in infection or wound complication outcomes; therefore, these data do not support its routine prophylactic use in primary TKA.
引用
- Bingol O, Karlidag T, Ozsoy HE, et al. Systemic Exposure and Renal Safety After Intrawound Vancomycin Powder in Primary Total Knee Arthroplasty: A Prospective Comparative Cohort Study. J Arthroplasty. 2026. PMID: 42843685. doi:10.1016/j.arth.2026.09.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。